Tamoxifen Therapy to Treat Pulmonary Arterial Hypertension

Summary

The main purpose of this clinical trial is to examine the feasibility and effects of tamoxifen in subjects with pulmonary arterial hypertension (PAH). The study will evaluate how well the drug is tolerated, and its impact on functional condition and selected biomarkers. Changes in tricuspid annular plane systolic excursion (TAPSE) and other parameters determined by transthoracic echocardiography will be evaluated as well as changes in additional metrics such as six minute walk test distance, quality of life assessments, and hormone levels.

Timeline

Start

2018-10-01

Primary completion

2023-06-14

Completion

2023-06-14

Drugs

Indications